Gene Editing: Off-Target Effects Should Be A Key Safety Focus During Development, US FDA Says

 
• By Sue Sutter
  
Missed target
Therapeutics incorporating gene editing require special attention to off-target effects. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies